A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake-Reference-Cited by-同舟云学术

A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake

Published:2007-09-01 Issue:9 Volume:92 Page:3531-3534
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Mannavola Deborah¹,Coco Paola²,Vannucchi Guia¹,Bertuelli Rossella²,Carletto Marco³,Casali Paolo G.²,Beck-Peccoz Paolo¹,Fugazzola Laura¹

Affiliation:

1. Department of Medical Sciences (D.M., G.V., P.B.-P., L.F.), Fondazione Policlinico Istituto di Ricovero e Cura a Carattere Scientifico, 20122 Milan, Italy

2. Department of Oncology (P.Co., R.B., P.Ca.), Istituto Nazionale dei Tumori, 20133 Milan, Italy

3. University of Milan and Endocrine Unit, and Nuclear Medicine Division (M.C.), Fondazione Policlinico Istituto di Ricovero e Cura a Carattere Scientifico, 20122 Milan, Italy

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/92/9/3531/10405201/jcem3531.pdf

Reference15 articles.

1. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer.;Abrams;Mol Cancer Ther,2003

2. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.;O’Farrell;Clin Cancer Res,2003

3. Activity of SU11248, a multitarget inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.;Motzer;J Clin Oncol,2006

4. New drug increases survival in stomach cancer;Susman;Lancet Oncol,2006

5. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast.;Abrams;Mol Cancer Ther,2003

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study;Cancer Immunology, Immunotherapy;2024-06-04

2. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function;Thyroid®;2024-02-01

3. The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review;International Journal of Clinical Pharmacy;2023-12-26

4. Prevalence and Associated Factors for Thyroid Dysfunction Among Patients On Targeted Therapy for Cancers: A Single-Center Study from Thailand;Journal of the ASEAN Federation of Endocrine Societies;2023-11-16

5. Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series;Biomedicines;2023-11-04